cmp target price q2 update: robust recovery across rs

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

©

Your success is our success

Emkay

India Equity Research | Retail

October 7, 2021

Company Update

Titan Company Refer to important disclosures at the end of this report

Q2 update: Robust recovery across divisions

Titan’s Q2 business update highlights a robust recovery and a strong performance

across divisions, with the jewelry division reporting a 2-year CAGR of 32%. Network

expansion has also been accelerated during the quarter. Full unlocking and the

upcoming festive/wedding season are likely to further boost revenues in the coming

quarters and may offer more upsides, in our view. Factoring in the strong growth

momentum, we increase our FY23/FY24 EPS estimates by 8-12%. Given the solid

growth and earnings outlook, we raise our Sep’22 TP to Rs2,530 (from Rs2,000),

valuing the stock at 65x Sep’23E EPS (from 55x Sep’23E EPS earlier). Retain Buy.

Jewelry grows 78% with 2-year CAGR of 32%: Excluding bullion sales of Rs3.9bn in the

base quarter, the Jewelry segment grew 78% in Q2FY22 with a strong 2-year CAGR of

32%, aided by pent-up demand and a 10% store addition CAGR (414 jewelry stores vs.

345 in Q2FY20). Management said pent-up demand after the second wave was seen in

gift purchases, occasions, milestone buying, weddings and investments in gold. While

studded sales saw strong double-digit growth, studded mix was indicated to be lower than

pre-Covid levels due to higher growth in plain gold sales. Since Titan’s entire network of

jewelry stores across formats has been hallmarking compliant, we expect faster share

gains from unorganized players. Enrollments in the Golden Harvest Scheme (GHS)

surpassed the pre-pandemic levels. Titan also introduced digital gold for digitally-savvy

young consumers. Mandatory hallmarking is effective in 256 districts in India. Tanishq and

other jewelry brands are now 100% compliant in all aspects.

Recovery in Watches/Eyewear also ahead of expectations: Watches and Eyewear

segments also posted a strong recovery and returned to pre-Covid levels with a 2-year

revenue CAGR of -2% and 3%, respectively. A faster recovery was aided by a 2%/6%

store addition CAGR in Watches/Eyewear, improvement in mall walk-ins and consistent

growth in the e-commerce channel. Titan added 8 stores for watches and 24 for eyewear

in Q2FY22.

Caratlane’s business remained on its strong growth trajectory with 95% growth, driven by

the launch of new merchandise and marketing initiatives. Other businesses (Taneira,

Fragrances and Accessories) grew 121%, aided by higher operational stores and healthy

recovery in retail, department stores and E-commerce. TEAL recorded a 43% decline.

Q2 expectations: Based on the update, we expect TTAN to report a solid 64% revenue

growth to Rs71bn (80% excl Rs3.9bn bullion sale in Q2FY21). Despite high plain gold mix,

operating margins should reach normalized levels of 11.5%, thanks to strong cost savings

seen in Q1 and some operating leverage. We estimate a PAT of Rs5.5bn vs. Rs2bn in

Q2FY21.

Please see our sector model portfolio (Emkay Alpha Portfolio): Consumer Goods & Retail (Page 7)

Relative price chart

Source: Bloomberg This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

Ashit Desai

[email protected]

+91 22 6612 1340

Devanshu Bansal

[email protected]

+91 22 6612 1385

-20

-12

-4

4

12

20

1150

1360

1570

1780

1990

2200

Oct-20Dec-20Feb-21Apr-21 Jun-21Aug-21Oct-21

%Rs

Titan Company (LHS) Rel to Nifty (RHS)

CMP Target Price

Rs 2,148 Rs 2,530 (▲) as of (October 6, 2021) 12 months

Rating Upside

BUY (■) 17.8 %

Change in Estimates

EPS Chg FY22E/FY23E (%) 3/8

Target Price change (%) 26.5

Target Period (Months) 12

Previous Reco BUY

Emkay vs Consensus

EPS Estimates

FY22E FY23E

Emkay 24.9 35.0

Consensus 21.1 28.6

Mean Consensus TP (12M) Rs 1,890

Stock Details

Bloomberg Code TTAN IN

Face Value (Rs) 1

Shares outstanding (mn) 888

52 Week H/L 2,207 / 1,154

M Cap (Rs bn/USD bn) 1,907 / 25.43

Daily Avg Volume (nos.) 12,49,860

Daily Avg Turnover (US$ mn) 31.3

Shareholding Pattern Jun '21

Promoters 52.9%

FIIs 18.4%

DIIs 9.9%

Public and Others 18.8%

Price Performance

(%) 1M 3M 6M 12M

Absolute 6 22 41 79

Rel. to Nifty 5 9 17 18

Financial Snapshot (Consolidated)

(Rs mn) FY20 FY21 FY22E FY23E FY24E

Revenue 2,10,515 2,16,440 2,88,092 3,66,974 4,26,813

EBITDA 24,666 17,240 34,438 47,368 58,022

EBITDA Margin (%) 11.7 8.0 12.0 12.9 13.6

APAT 14,927 9,740 22,090 31,088 38,653

EPS (Rs) 16.8 11.0 24.9 35.0 43.5

EPS (% chg) 1.3 (34.7) 126.8 40.7 24.3

ROE (%) 23.4 13.8 26.4 29.6 29.0

P/E (x) 127.7 195.8 86.3 61.3 49.3

EV/EBITDA (x) 77.1 108.6 54.6 39.5 31.8

P/BV (x) 28.6 25.4 20.6 16.2 12.8

Source: Company, Emkay Research

http://www.emkayglobal.com/

Titan Company (TTAN IN) India Equity Research | Company Update


October 7, 2021 | 2

Exhibit 1: Quarterly Preview: We expect robust recovery on all fronts in Q2FY22E

Y/E, Mar (Rs. mn) 2QFY21 1QFY22 2QFY22E YoY (%) QoQ (%)

Revenue 43,180 32,490 70,703 63.7 117.6

EBITDA 2,940 1,440 8,163 177.7 466.9

EBITDA Margin, % 6.8% 4.4% 11.5% 470 710

Adjusted PAT 1,990 610 5,523 177.5 805.3

Adjusted EPS 2.2 0.7 6.2 177.5 805.3


Exhibit 2: Key Growth assumptions (%)

Particulars FY20 FY21 FY22E FY23E FY24E

Jewellery 4.4 11.3 30.2 25.7 16.1

Watches 7.2 -39.6 57.5 36.5 13.3

Eyewear 6.4 -31.1 51.5 31.8 17.1

Caratlane 49.3 13.8 40.5 50.0 30.0

TEAL 34.2 -23.7 21.8 10.0 10.0


Exhibit 3: Changes in estimates

Y/E, Mar (Rs. mn) FY22E FY23E FY24E

Earlier Revised % Change Earlier Revised % Change Earlier Revised % Change

Revenues 2,72,108 2,88,092 5.9 3,22,715 3,66,974 13.7 3,72,786 4,26,813 14.5

EBITDA 33,166 34,438 3.8 42,914 47,368 10.4 51,126 58,022 13.5

EBITDA Margin (%) 12.2 12.0 -20 bps 13.3 12.9 -40 bps 13.7 13.6 -10 bps

APAT 21,487 22,090 2.8 28,691 31,088 8.4 34,629 38,653 11.6

EPS (Rs) 24.2 24.9 2.8 32.3 35.0 8.4 39.0 43.5 11.6


Exhibit 4: Titan: Growth construct of the business from demand side

CAGR (%) CAGR (%) CAGR

FY12 FY19 FY12-19 FY35E FY19-35E >FY35E

Gold Jewelry sales volume (tons) 568 604 0.9 600 (0.0) 0.0

Gold Price (Rs/10g) 25,070 28,339 1.8 86,351 7.2 5.0

Premiumisation benefit (%) 0.7 2.5 1.0

Share of organised segment (%) 26.0 32.0 3.0 48.0 2.6 1.0

Share of Titan in organized segment (%) 11.6 17.0 5.6 29.0 3.4 1.50

Titan Jewelry revenues 70,642 1,60,296 12.4 18,40,265 16.5 8.72

Jewelry segment EBIT margin (%) 9.9 12.2 3.0 13.0 0.4

Titan Jewelry EBIT 6,976 19,480 15.8 2,39,234 17.0

Titan consol revenues 89,227 1,97,785 12.0 21,19,625 16.0 8.2

Consol. EBIT margin (%) 8.8 9.2 0.7 13.0 2.2

Titan consol. EBIT 7,880 18,287 12.8 2,75,551 18.5 8.2

Source: WGC, Company, Emkay Research




October 7, 2021 | 3

Exhibit 5: Titan: Target P/E multiple derived from a two-stage dividend growth model

Revenue CAGR [FY22E-25E] (%) 19.8

EPS CAGR [FY22E-25E] (%) 27.2

Stage-1: FY25E-35E

EPS in Yr-0 [FY25E] (Rs) 51.2

EPS in Yr-1 (Rs) 59.7

EPS CAGR (%) 16.5

Years of growth [n] 10.0

RoE (%) 35.0

CoE (%) 11.10

Implied DPR (%) 53

Terminal stage: >FY35E

EPS growth (%) 8.5

RoE (%) 35.0

Implied DPR (%) 76

Fair value P/E in Mar'25E (x) 49.5

Fair value in Mar'25E (x) 2,956

Fair value in Sep'22E (x) 2,272

NPV of dividends in FY22E-25E (Rs/share) 26

Overall fair value in Sep'22E (Rs/share) 2,298

Sep'23E EPS (Rs) 39.3

Implied fair value P/E in Sep'22E (x) 58.5

Premium applied to FV (%) [a] 10.0

Implied target P/E in Sep'22E (x) 64.4

Implied TP in Sep'22E (x) 2,528

CMP (Rs/share) 2,150

Upside (%) 18

Source: Emkay Research, [a] EBIT margin expansion will likely be front-loaded than assumed

Exhibit 6: TTAN’s 1-Yr fwd PE valuation chart


0

500

1000

1500

2000

2500

Oct-

13

Fe

b-1

4

Jun

-14

Oct-

14

Fe

b-1

5

Ju

n-1

5

Oct-

15

Fe

b-1

6

Ju

n-1

6

Oct-

16

Fe

b-1

7

Ju

n-1

7

Oct-

17

Fe

b-1

8

Ju

n-1

8

Oct-

18

Feb-1

9

Ju

n-1

9

Oct-

19

Fe

b-2

0

Ju

n-2

0

Oct-

20

Fe

b-2

1

Ju

n-2

1

Oct-

21

Titan-P/E band

35x

20x

50x

65x




October 7, 2021 | 4

Key Financials (Consolidated)

Income Statement

Y/E Mar (Rs mn) FY20 FY21 FY22E FY23E FY24E

Revenue 2,10,515 2,16,440 2,88,092 3,66,974 4,26,813

Expenditure 1,85,850 1,99,200 2,53,654 3,19,606 3,68,791

EBITDA 24,666 17,240 34,438 47,368 58,022

Depreciation 3,480 3,750 4,241 5,117 5,787

EBIT 21,186 13,490 30,197 42,250 52,235

Other Income 1,532 1,860 1,860 2,222 2,656

Interest expenses 1,662 2,030 2,446 2,811 3,115

PBT 21,057 13,320 29,612 41,661 51,776

Tax 6,090 3,530 7,442 10,473 13,022

Extraordinary Items 0 0 0 0 0

Minority Int./Income from Assoc. (40) (50) (80) (100) (100)

Reported Net Income 14,927 9,740 22,090 31,088 38,653

Adjusted PAT 14,927 9,740 22,090 31,088 38,653

Balance Sheet


Equity share capital 888 888 888 888 888

Reserves & surplus 65,800 74,088 91,739 1,16,612 1,48,163

Net worth 66,688 74,976 92,627 1,17,500 1,49,051

Minority Interest 44 44 44 44 44

Loan Funds 19,658 14,210 13,407 14,118 14,628

Net deferred tax liability (1,259) (590) (356) (105) 181

Total Liabilities 85,131 88,640 1,05,722 1,31,558 1,63,905

Net block 24,864 23,730 24,189 24,272 23,685

Investment 6,127 33,030 33,041 33,041 33,041

Current Assets 1,00,067 1,03,920 1,26,137 1,68,076 2,16,184

Cash & bank balance 3,811 5,600 14 10,064 33,114

Other Current Assets 6,959 7,520 7,520 7,520 8,272

Current liabilities & Provision 47,340 73,590 79,195 95,382 1,10,555

Net current assets 52,728 30,330 46,941 72,694 1,05,629

Misc. exp 0 0 0 0 0

Total Assets 85,131 88,640 1,05,722 1,31,558 1,63,905

Cash Flow


PBT (Ex-Other income) (NI+Dep) 21,017 13,270 29,532 41,561 51,676

Other Non-Cash items 0 0 0 0 0

Chg in working cap (18,456) 24,085 (21,963) (15,452) (9,599)

Operating Cashflow 540 40,390 6,813 23,565 37,957

Capital expenditure (3,027) (1,196) (2,500) (3,000) (3,000)

Free Cash Flow (2,487) 39,194 4,313 20,565 34,957

Investments (444) (26,914) 0 0 0

Other Investing Cash Flow 0 0 0 0 0

Investing Cashflow (4,885) (28,099) (2,511) (3,000) (3,000)

Equity Capital Raised 2 0 0 0 0

Loans Taken / (Repaid) 6,747 (5,594) (1,560) 0 0

Dividend paid (incl tax) (5,351) (3,551) (4,439) (6,215) (7,102)

Other Financing Cash Flow (2,244) 673 (1,443) (1,488) (1,690)

Financing Cashflow (2,508) (10,502) (9,888) (10,514) (11,908)

Net chg in cash (6,854) 1,789 (5,586) 10,050 23,050

Opening cash position 10,665 3,811 5,600 14 10,064

Closing cash position 3,811 5,600 14 10,064 33,114





October 7, 2021 | 5

Key Ratios

Profitability (%) FY20 FY21 FY22E FY23E FY24E

EBITDA Margin 11.7 8.0 12.0 12.9 13.6

EBIT Margin 10.1 6.2 10.5 11.5 12.2

Effective Tax Rate 28.9 26.5 25.1 25.1 25.2

Net Margin 7.1 4.5 7.7 8.5 9.1

ROCE 36.0 21.9 38.4 42.4 41.1

ROE 23.4 13.8 26.4 29.6 29.0

RoIC 35.9 22.1 50.5 53.5 57.1

Per Share Data (Rs) FY20 FY21 FY22E FY23E FY24E

EPS 16.8 11.0 24.9 35.0 43.5

CEPS 20.7 15.2 29.7 40.8 50.1

BVPS 75.1 84.5 104.3 132.3 167.9

DPS 5.0 4.0 5.0 7.0 8.0

Valuations (x) FY20 FY21 FY22E FY23E FY24E

PER 127.7 195.8 86.3 61.3 49.3

P/CEPS 103.6 141.3 72.4 52.7 42.9

P/BV 28.6 25.4 20.6 16.2 12.8

EV / Sales 9.0 8.7 6.5 5.1 4.3

EV / EBITDA 77.1 108.6 54.6 39.5 31.8

Dividend Yield (%) 0.2 0.2 0.2 0.3 0.4

Gearing Ratio (x) FY20 FY21 FY22E FY23E FY24E

Net Debt/ Equity (0.1) (0.4) (0.3) (0.3) (0.4)

Net Debt/EBIDTA (0.2) (1.9) (0.8) (0.8) (1.1)

Working Cap Cycle (days) 84.8 41.7 59.5 62.3 62.0

Growth (%) FY20 FY21 FY22E FY23E FY24E

Revenue 6.4 2.8 33.1 27.4 16.3

EBITDA 23.9 (30.1) 99.8 37.5 22.5

EBIT 15.9 (36.3) 123.9 39.9 23.6

PAT 7.5 (34.7) 126.8 40.7 24.3

Quarterly (Rs mn) Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22E

Revenue 43,180 72,870 71,350 32,490 70,703

EBITDA 2,940 8,580 7,950 1,440 8,163

EBITDA Margin (%) 6.8 11.8 11.1 4.4 11.5

PAT 1,990 4,190 5,290 610 5,523

EPS (Rs) 2.2 4.7 6.0 0.7 6.2


Shareholding Pattern (%) Jun-20 Sep-20 Dec-20 Mar-21 Jun-21

Promoters 52.9 52.9 52.9 52.9 52.9

FIIs 17.6 18.1 18.6 18.1 18.4

DIIs 10.8 11.0 10.9 11.1 9.9

Public and Others 18.7 18.1 17.6 17.9 18.8

Source: Capitaline




October 7, 2021 | 6

RECOMMENDATION HISTORY TABLE

Date Closing

Price TP

Period (months)

Rating Analyst

04-Aug-21 1,800 2,000 12m Buy Ashit Desai

07-Jul-21 1,727 1,810 12m Buy Ashit Desai

30-Apr-21 1,492 1,725 12m Buy Ashit Desai


11-Feb-21 1,525 1,650 12m Buy Ashit Desai

07-Dec-20 1,425 1,450 12m Buy Ashit Desai

26-Nov-20 1,327 1,450 12m Buy Ashit Desai

29-Oct-20 1,178 1,300 12m Buy Ashit Desai

07-Oct-20 1,254 1,215 12m Buy Ashit Desai


10-Jun-20 977 1,100 12m Buy Ashit Desai

14-Apr-20 967 1,100 12m Buy Ashit Desai

08-Apr-20 913 1,100 12m Buy Ashit Desai

05-Feb-20 1,280 1,240 12m Hold Ashit Desai

25-Dec-19 1,204 1,230 12m Hold Ashit Desai

06-Nov-19 1,156 1,230 12m Hold Ashit Desai

20-Sep-19 1,264 1,385 12m Buy Ashit Desai


08-May-19 1,089 1,200 12m Buy Ashit Desai


02-Feb-19 992 1,080 12m Buy Ashit Desai

09-Nov-18 848 1,000 12m Buy Ashit Desai


RECOMMENDATION HISTORY CHART

Source: Bloomberg, Company, Emkay Research

740

1027

1314

1601

1888

2175

09

-Oct-

18

08

-Apr-

19

06

-Oct-

19

04

-Apr-

20

02

-Oct-

20

01

-Apr-

21

29

-Sep

-21

BUY Hold SellAccumulate Reduce PriceTarget Price




October 7, 2021 | 7

Emkay Alpha Portfolio – Consumer Goods & Retail

EAP sector portfolio

Company Name BSE200 Weight

EAP Weight

OW/UW (%)

OW/UW (bps)

EAP Weight (Normalised)

Consumer Goods & Retail 10.46 10.46 0% 0 100.00

Asian Paints 1.41 0.50 -64% -91 4.78

Berger Paints 0.19 0.00 -100% -19 0.00

Britannia Industries 0.45 0.55 23% 10 5.25

Colgate-Palmolive 0.22 0.24 9% 2 2.29

Dabur India 0.35 0.39 9% 3 3.68

Emami 0.11 0.12 2% 0 1.10

Godrej Consumer Products 0.38 0.37 -1% -1 3.58

Hindustan Unilever 2.34 1.78 -24% -55 17.06

ITC 2.02 2.09 4% 8 20.00

Marico 0.28 0.32 13% 4 3.03

Nestle India 0.68 0.42 -38% -26 4.00

Pidilite Industries 0.36 0.00 -100% -36 0.00

Radico Khaitan 0.00 0.31 NA 31 3.00

United Breweries 0.11 0.52 387% 42 5.00

United Spirits 0.00 0.31 NA 31 3.00

Varun Beverages 0.13 0.21 59% 8 2.00

ABFRL 0.07 0.10 46% 3 0.97

Jubilant FoodWorks 0.31 0.29 -7% -2 2.76

Page Industries 0.18 0.42 128% 24 4.00

Titan Company 0.88 1.05 19% 17 10.00

TCNS Clothing 0.00 0.21 NA 21 2.05

Westlife Development 0.00 0.26 NA 26 2.45

Cash 0.00 0.00 NA 0 0.00

Source: Emkay Research

* Not under coverage: Equal Weight

High Conviction/Strong Over Weight High Conviction/Strong Under Weight

Sector portfolio NAV

Base Latest

1-Apr-19 6-Oct-20 6-Apr-21 6-Jul-21 3-Sep-21 5-Oct-21

EAP - Consumer Goods & Retail 100.0 103.8 121.5 131.2 145.7 149.0

BSE200 Neutral Weighted Portfolio (ETF) 100.0 99.9 117.5 125.2 138.5 139.9

*Performance measurement base date 1st April 2019


Price Performance (%)

1m 3m 6m 12m

EAP - Consumer Goods & Retail 2.3% 13.5% 22.7% 43.6%

BSE200 Neutral Weighted Portfolio (ETF) 1.0% 11.7% 19.0% 40.0%


NAV chart


Please see our model portfolio (Emkay Alpha Portfolio): Nifty

Please see our model portfolio (Emkay Alpha Portfolio): SMID “Emkay Alpha Portfolio – SMID and Nifty are a supporting document to the Emkay Alpha

Portfolios Report and is updated on regular intervals”

75

91

107

123

139

155

Apr-19 Jul-19 Nov-19 Mar-20 Jul-20 Oct-20 Feb-21 Jun-21 Sep-21

NAV

EAP - Consumer Goods & Retail BSE200 Neutral Weighted Portfolio (ETF)

Analyst: Ashit Desai

Contact Details

[email protected]

+91 22 6612 1340

Sector

Consumer Goods & Retail

Analyst bio

Ashit Desai holds a PGDM and FRM (US

GARP) with 13 years of research

experience on the sell side. His team

currently covers 24 stocks in the Indian

Consumer and Retail space.


https://web3.emkayglobal.com/ResearchAccess/Upload/Nifty_Oct21.pdf

https://web3.emkayglobal.com/ResearchAccess/Upload/SMID_Oct21.pdf

https://web3.emkayglobal.com/ResearchAccess/Upload/SMID_Oct21.pdf

mailto:[email protected]



October 7, 2021 | 8

Emkay Rating Distribution

Ratings Expected Return within the next 12-18 months.

BUY Over 15%

HOLD Between -5% to 15%

SELL Below -5%

Completed Date: 07 Oct 2021 05:00:01 (SGT) Dissemination Date: 07 Oct 2021 05:01:01 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL): Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read “Risk Disclosure Document for Capital Market and Derivatives Segments” as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.





October 7, 2021 | 9

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL) The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate1 does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests2 in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL. 1 An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst. 2 Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm’s length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-: 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of October 7, 2021 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced: 3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research

report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.

4. EGFSL , its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s does not have any material conflict of interest in the securities recommended in this report as of October 7, 2021.

5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative’s does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the October 7, 2021

6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.

7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.

8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the October 7, 2021




October 7, 2021| 10

RESTRICTIONS ON DISTRIBUTION

General This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

Australia This report is not for distribution into Australia.

Hong Kong This report is not for distribution into Hong Kong.

Indonesia This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.

Malaysia This report is not for distribution into Malaysia.

Singapore

This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.

Thailand This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.

United Kingdom

This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.

In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.

Dubai International Financial Centre

This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.

United Arab Emirates

This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.

United States

DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.

Other jurisdictions In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com


www.emkayglobal.com

cmp target price q2 update: robust recovery across rs

Documents